1-10 of 10
Mihaela Obreja
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Michael J. Burke, David S. Ziegler, Francisco Bautista, Andishe Attarbaschi, Lia Gore, Franco Locatelli, Maureen M. O'Brien, Melinda Pauly, Mihaela Obreja, Christopher L. Morris, Andre Baruchel
Journal: Blood
Blood (2021) 138 (Supplement 1): 1235.
https://doi.org/10.1182/blood-2021-147588
Published: 2021
Journal Articles

Phase 2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

David S. Ziegler, Van Huynh, Michael J. Burke, Lia Gore, Franco Locatelli, Maureen M. O'Brien, Christopher Kim, Mihaela Obreja, Christopher L. Morris, André Baruchel
Journal: Blood
Blood (2021) 138 (Supplement 1): 4403.
https://doi.org/10.1182/blood-2021-153865
Published: 2021
Journal Articles

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Michael J. Burke, MD, David S. Ziegler, MBBS, FRACP, MD, Francisco José Bautista Sirvent, MD PhD, Andishe Attarbaschi, MD, Lia Gore, MD, Franco Locatelli, MD PhD, Maureen M O'Brien, MD, Melinda Pauly, MD, Mihaela Obreja, PhD, Christopher L. Morris, PhDMD, Andre Baruchel, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3873.
https://doi.org/10.1182/blood-2019-127350
Published: 2019
Journal Articles

Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: An Analysis of Overall Survival in Subgroups from the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, MD PhD, Hartmut Goldschmidt, MD, Jesus F San-Miguel, MD PhD, Julie Blaedel, Mihaela Obreja, Zhao Yang, Zsolt Szabo, Xavier Leleu, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1964.
https://doi.org/10.1182/blood-2018-99-112189
Published: 2018
Journal Articles

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

A. Keith Stewart, MBChB, MBA, David Siegel, MD PhD, Heinz Ludwig, MD, Thierry Facon, MD, Hartmut Goldschmidt, MD, Andrzej J. Jakubowiak, MD, Jesus F. San Miguel, MD, Mihaela Obreja, Julie Blaedel, Meletios A. Dimopoulos
Journal: Blood
Blood (2017) 130 (Supplement 1): 743.
https://doi.org/10.1182/blood.V130.Suppl_1.743.743
Published: 2017
Journal Articles

Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, Hartmut Goldschmidt, MD, Jesus F San Miguel, MD PhD, Joseph Mikhael, MD, Lucy DeCosta, MSc, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Zsolt Szabo, MD, Xavier Leleu, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3120.
https://doi.org/10.1182/blood.V130.Suppl_1.3120.3120
Published: 2017
Journal Articles

Relapsed or Refractory Multiple Myeloma Patients Treated with Second-Line Carfilzomib and Categorized By Prior Exposure to Bortezomib: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, Hartmut Goldschmidt, MD, Jesus F San Miguel, MD PhD, Joseph Mikhael, MD, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Karim Saad Iskander, Xavier Leleu, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1840.
https://doi.org/10.1182/blood.V130.Suppl_1.1840.1840
Published: 2017
Journal Articles

Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies

Irene M. Ghobrial, MD, Michael R. Savona, MD, Ravi Vij, David S. Siegel, Ashraf Badros, Jonathan L. Kaufman, MD, Noopur Raje, MD, Andrzej Jakubowiak, MD PhD, Mihaela Obreja, Jesus G. Berdeja, MD
Journal: Blood
Blood (2016) 128 (22): 2110.
https://doi.org/10.1182/blood.V128.22.2110.2110
Published: 2016
Journal Articles

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Clinical Trials & Observations
Hervé Avet-Loiseau, Rafael Fonseca, David Siegel, Meletios A. Dimopoulos, Ivan Špička, Tamás Masszi, Roman Hájek, Laura Rosiñol, Vesselina Goranova-Marinova, Georgi Mihaylov, Vladimír Maisnar, Maria-Victoria Mateos, Michael Wang, Ruben Niesvizky, Albert Oriol, Andrzej Jakubowiak, Jiri Minarik, Antonio Palumbo, William Bensinger, Vishal Kukreti, Dina Ben-Yehuda, A. Keith Stewart, Mihaela Obreja, Philippe Moreau
Journal: Blood
Blood (2016) 128 (9): 1174–1180.
https://doi.org/10.1182/blood-2016-03-707596
Published: 2016
Journal Articles

Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)

Hervé Avet-Loiseau, MD, Rafael Fonseca, MD, David Siegel, MD PhD, Meletios A. Dimopoulos, Ivan Spicka, Tamás Masszi, Roman Hájek, Laura Rosiñol, Vesselina Goranova-Marinova, Georgi Mihaylov, Vladimír Maisnar, Maria-Victoria Mateos, Michael Wang, MD, Ruben Niesvizky, MD, Albert Oriol, Andrzej Jakubowiak, MD PhD, Jiri Minarik, Antonio Palumbo, William Bensinger, MD, Vishal Kukreti, Dina Ben-Yehuda, Margaret Tonda, Mihaela Obreja, Philippe Moreau
Journal: Blood
Blood (2015) 126 (23): 731.
https://doi.org/10.1182/blood.V126.23.731.731
Published: 2015